Moreover, FXR agonists, such as obeticholic acid (OCA, 6α-ethyl-chenodeoxycholic acid), a semi-synthetic variant of chenodeoxycholic acid, have been shown to produce beneficial effects on cholestasis11, steatosis12–15, and fibrosis in experimental models14–17, whereas the effect on obesity-associated liver fibrosis remains to be fully elucidated12. This evidence concerns the gene NR1H4 and obesity due to melanocortin 4 receptor deficiency.